Notably, this represents a new PFS and ORR record for the combination of CDK4/6i and AI in the first-line treatment of advanced HR + /HER2- breast cancer, further solidifying its role as the first-line therapy for endocrine-sensitive patients with HR + /HER2- advanced breast cancer [24]. The gene discussed is ERBB2; the disease is breast carcinoma.